KV

Klaus Veitinger

Venture Partner at OrbiMed Advisors | Experienced Biopharmaceutical Executive and Investor | Brain Cancer Advocate

New York City Metropolitan Area

Investor
VC

Invests in

  • Min Investment:

    $1,000,000.00

  • Max Investment:

    $75,000,000.00

  • Target Investment:

    $4,000,000.00

Skills

CEO
Venture Capital
Pharmaceutical Industry
Biotechnology
Life Sciences
Start ups
Private Equity
Turn Around Management
Clinical Trials
FDA
Regulatory Affairs
Clinical Development
Due Diligence
Business Strategy
Biopharmaceuticals
Commercialization
Research and Development (R&D)
Licensing
Mergers & Acquisitions (M&A)
Business Development

Education

Lists including Klaus

AM
AR
AG
AH

Based in NYC

2600 people

AT
AS
AT
AH

All Series A Investors

14752 people

Investments

Sparrow Pharmaceuticals

Series A

Total Funding: $60M

Alpheus Medical

Series A

Total Funding: $30M

Neurogastrx

Series A

Total Funding: $110M

Promentis Pharmaceuticals

Series C

Total Funding: $26M

Work Experience

O
OrbiMed

2007

  • Venture Partner

    2007

SP
Sparrow Pharmaceuticals, Inc.

2021

  • Chairman of the Board

    2021

AM
Alpheus Medical, Inc

2020

  • Executive Chairman

    2020

NI
Neurogastrx, Inc.

2017

  • Chairman of the Board

    2017

FDA - Brain Cancer Research Roundtable

2021

  • Investor Representative

    2021

s
scPharmaceuticals

2017

  • Board Member

    2017

CR
Cure Rare Disease

2024

  • Board Member

    2024

Af
Alliance for Cancer Gene Therapy

2020

  • Board Member

    2020

TI
Tricida, Inc.

2013 - 2023

  • Chairman of the Board

    2013 - 2023

Symbiomix Therapeutics, LLC

2014 - 2017

  • CEO

    2014 - 2017